H.C. Wainwright analyst Ed Arce raised the firm’s price target on Cidara Therapeutics (CDTX) to $35 from $24 and keeps a Buy rating on the shares following the Q4 report. Given positive data from NAVIGATE are expected to support a pivotal Phase 3 study, H.C. Wainwright expects the top-line data readout in the second half of 2025 as the next major potential catalyst for the shares, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing
- Cidara Therapeutics Advances with Strong Financial Backing
- Buy Rating for Cidara Therapeutics Driven by Phase 2b Trial Progress and Strong Financial Position
- Cidara Therapeutics reports Q4 EPS ($5.37) vs. (71c) last year
- Six new option listings and one option delisting on February 26th